Public Release: 

Preclinical candidate for HIV therapy

Proceedings of the National Academy of Sciences

Researchers used computational and structure-based design to develop compound I, a preclinical candidate for HIV therapy; compound I, a non-nucleoside reverse transcriptase inhibitor, exhibited synergistic properties with existing HIV-1 drugs and clinical candidates at the cellular level as well as suppressed viral loads and prevented human CD4+ T-cell loss in HIV-1-infected humanized mice, and a long-acting version of compound I sustained plasma drug concentrations and effectiveness for approximately 3 weeks in mice, suggesting that the compound might have a role in pre-exposure treatments.

###

Article #17-17932: "From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection," by Shalley Kudalkar et al.

MEDIA CONTACT: William Jorgensen, Yale University School of Medicine, New Haven, CT; tel: 860-767-8032; e-mail: <william.jorgensen@yale.edu>; Karen Anderson, Yale University School of Medicine, New Haven, CT; tel: 203-988-3535; e-mail: <karen.anderson@yale.edu>

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.